A phase II, open label study of everolimus with fulvestrant in postmenopausal women with hormone receptor-positive HER-2 negative AI and fulvestrant treated, locally advanced or metastatic breast cancer (mBC), who progressed on or after mTor inhibitor based treatment.

Trial Profile

A phase II, open label study of everolimus with fulvestrant in postmenopausal women with hormone receptor-positive HER-2 negative AI and fulvestrant treated, locally advanced or metastatic breast cancer (mBC), who progressed on or after mTor inhibitor based treatment.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Everolimus (Primary) ; Fulvestrant
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top